View Item 

Show simple item record

Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation

dc.contributor.authorGrupp, Stephan A.en_US
dc.contributor.authorDvorak, Christopher C.en_US
dc.contributor.authorNieder, Michael L.en_US
dc.contributor.authorLevine, John E.en_US
dc.contributor.authorWall, Donna A.en_US
dc.contributor.authorLangholz, Bryanen_US
dc.contributor.authorPulsipher, Michael A.en_US
dc.date.accessioned2013-05-02T19:34:55Z
dc.date.available2014-08-01T19:11:34Zen_US
dc.date.issued2013-06en_US
dc.identifier.citationGrupp, Stephan A.; Dvorak, Christopher C.; Nieder, Michael L.; Levine, John E.; Wall, Donna A.; Langholz, Bryan; Pulsipher, Michael A. (2013). "Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation." Pediatric Blood & Cancer 60(6): 1044-1047. <http://hdl.handle.net/2027.42/97445>en_US
dc.identifier.issn1545-5009en_US
dc.identifier.issn1545-5017en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97445
dc.description.abstractThe role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi‐institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant‐associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN‐0501, in close collaboration with the BMT‐CTN. Pediatr Blood Cancer 2013; 60: 1044–1047. © 2012 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherTransplantationen_US
dc.subject.otherSCTen_US
dc.subject.otherStem Cell Transplantationen_US
dc.titleChildren's Oncology Group's 2013 blueprint for research: Stem cell transplantationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan School of Medicine, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherPrimary Children's Medical Center/Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utahen_US
dc.contributor.affiliationotherChildren's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvaniaen_US
dc.contributor.affiliationotherBenioff Children's Hospital, University of California San Francisco, San Francisco, Californiaen_US
dc.contributor.affiliationotherMoffitt Cancer Center, Tampa, Floridaen_US
dc.contributor.affiliationotherUniversity of Manitoba/CancerCare Manitoba, Winnipeg, MB, Canadaen_US
dc.contributor.affiliationotherChildren's Oncology Group Statistics & Data Center, University of Southern California, Arcadia, Californiaen_US
dc.contributor.affiliationotherChildren's Hospital of Philadelphia, CTRB 3006, 3501 Civic Center Blvd., Philadelphia, PA 19104‐4318.en_US
dc.identifier.pmid23255402en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97445/1/24437_ftp.pdf
dc.identifier.doi10.1002/pbc.24437en_US
dc.identifier.sourcePediatric Blood & Canceren_US
dc.identifier.citedreferenceMilone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453 – 1464.en_US
dc.identifier.citedreferenceKalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med 2011; 3: 95ra73.en_US
dc.identifier.citedreferencePorter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor‐modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725 – 733.en_US
dc.identifier.citedreferenceLocatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG‐MDS/EBMT trial. Blood 2005; 105: 410 – 419.en_US
dc.identifier.citedreferenceKreissman SG, Villablanca JG, Seeger RC, et al. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant for high‐risk neuroblastoma (HR‐NB) employing immunomagnetic purged versus unpurged PBSC: A Children's Oncology Group study. J Clin Oncol 2008; 26: 10011.en_US
dc.identifier.citedreferencePulsipher M, Langholz B, Wall D, et al. A randomized trial of sirolimus‐based graft versus host disease (GVHD) prophylaxis after hematopoietic stem cell tansplantation (HSCT) in selected patients with CR1 and CR2 ALL: Results from Children's Oncology Group study ASCT 0431. Blood 2011; 118: 731.en_US
dc.identifier.citedreferenceUberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft‐versus‐host disease. Biol Blood Marrow Transplant 2005; 11: 680 – 687.en_US
dc.identifier.citedreferenceFrangoul H, Nemecek ER, Billheimer D, et al. A prospective study of G‐CSF primed bone marrow as a stem‐cell source for allogeneic bone marrow transplantation in children: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood 2007; 110: 4584 – 4587.en_US
dc.identifier.citedreferenceYanik GA, Ho VT, Levine JE, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008; 112: 3073 – 3081.en_US
dc.identifier.citedreferencePulsipher MA, Wall DA, Grimley M, et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009; 147: 691 – 699.en_US
dc.identifier.citedreferenceTeachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: An effective combination to treat acute lymphoblastic leukemia. Blood 2008; 112: 2020 – 2023.en_US
dc.identifier.citedreferenceGrupp SA, June CH. Adoptive cellular therapy. Curr Top Microbiol Immunol 2011; 344: 149 – 172.en_US
dc.identifier.citedreferenceTeachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI‐779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006; 107: 1149 – 1155.en_US
dc.identifier.citedreferenceTeachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009; 145: 569 – 580.en_US
dc.identifier.citedreferenceCooperman J, Neely R, Teachey DT, et al. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells 2004; 22: 1111 – 1120.en_US
dc.identifier.citedreferenceBrown VI, Seif AE, Reid GS, et al. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunol Res 2008; 42: 84 – 105.en_US
dc.identifier.citedreferenceBrown VI, Hulitt J, Fish J, et al. Thymic stromal‐derived lymphopoietin induces proliferation of pre‐B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin‐7Ralpha signaling. Cancer Res 2007; 67: 9963 – 9970.en_US
dc.identifier.citedreferenceYanik G, Hellerstedt B, Custer J, et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 395 – 400.en_US
dc.identifier.citedreferenceBarrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011; 2212: 1575 – 1586.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
24437_ftp.pdf
Size:
79.04KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.